Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celgosivir and Modipafant in Uncomplicated Dengue Fever
NCT02569827Phase 2Withdrawn
- Sponsor
- Singapore General Hospital
- Start
- Dec 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of celgosivir and modipafant in dengue fever (6 cohorts), sponsored by Singapore General Hospital. Primary endpoints: Viral load Area Under the Curve for viremia and Platelet nadir. Planned start Dec 2018; status: withdrawn.
02
Drugs
celgosivirmodipafant
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT02569827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02569827.